SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lizard

LIZARD CRYPTO is aggressively trending as its dedicated community rallies, actively buying recent dips and pushing for new all-time highs, fueled by aspirations of it becoming the next major meme coin.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

ICP is trending as its community actively discusses the impact of its Mission 70 tokenomics and growing real-world adoption through national subnet launches. Despite market volatility, proponents highlight rising network activity and its unique position as a decentralized cloud and AI infrastructure as key long-term drivers.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as its QNX software secures pivotal roles in next-generation vehicles from BMW and Volvo, powered by new platforms like Alloy Kore, igniting community discussion on the company's long-term growth potential in Software-Defined Vehicles and embedded AI despite consistent frustration over its stagnant stock price.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending as its highly anticipated Super App and revenue-sharing model are poised to launch, solidifying its role as Solana's privacy layer. The community is actively accumulating, emphasizing its undervalued market cap, upcoming full token circulation, and the potential of its utility-focused ecosystem with partnerships like GhostwareOS.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is currently trending amid an FTC lawsuit alleging anti-competitive rental ad practices and competitive threats from Google's expansion into real estate listings. Community sentiment is sharply divided between investors viewing the stock as oversold with potential for a rebound due to AI integrations and strong market share, and those concerned about ongoing market declines and new competition.

Alchemy Pay

Alchemy Pay (ACH) is trending as the community anticipates the imminent launch of its Alchemy Chain testnet, a major upgrade that will transform ACH into a Layer-1/Layer-2 blockchain with native gas token utility. This development, alongside new partnerships and expanded licenses, is generating buzz around ACH's role in compliant stablecoin payments and fiat-crypto settlement.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Arbitrum is trending as it solidifies its position as a premier Ethereum Layer 2 for real-world asset tokenization, fueled by key institutional adoptions like Robinhood for tokenized stocks and PayPal for stablecoins, even as the community debates the impact of ongoing token unlocks.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is trending following positive Phase 2 data for its Prader-Willi syndrome therapy, igniting significant community discussion around the drug's market potential and increasing buyout speculation, all while analysts upgrade targets ahead of a key hypothalamic obesity regulatory decision.

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Danaher Corp.

Danaher is trending due to its $9.9 billion all-cash acquisition of Masimo, which has thrilled Masimo shareholders with a substantial premium. Conversely, Danaher investors are showing apprehension over the significant price tag and short-term implications, despite the strategic expansion into patient monitoring within diagnostics.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is trending as the Supreme Court's ruling to strike down most of Trump's emergency tariffs has spurred broad market gains, while investors also focus on evolving Federal Reserve rate expectations and leadership changes impacting central bank independence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference

C4 Therapeutics (NASDAQ:CCCC) executives outlined plans to advance their lead multiple myeloma program and expand the company's broader targeted protein degradation (TPD) platform during a fireside...

FY2028 EPS Forecast for C4 Therapeutics Reduced by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Stock analysts at Brookline Capital Management reduced their FY2028 earnings per share (EPS) estimates for shares of C4 Therapeutics in a report...

Leonard Reyno Sells 10,000 Shares of C4 Therapeutics (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) insider Leonard Reyno sold 10,000 shares of the firm's stock in a transaction on Friday, January 16th. The shares were sold at an average price...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat Ratings...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 7,172,653...

C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC)

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 5,066 call options on the company. This is an...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One...

FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Investment analysts at Brookline Capital Management decreased their FY2028 EPS estimates for C4 Therapeutics in a report issued on Thursday...

C4 Therapeutics (NASDAQ:CCCC) Issues Quarterly Earnings Results

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CCCC News

CCCCC4 Therapeutics Inc